Your Web Site
News source: Business Wire The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase I/II study of elotuzumab (also known as Huluc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with VELCADE(R) (bortezomib) for Injection for the treatment of relapsed multiple myeloma. This study, sponsored by PDL BioPharma, Inc., and conducted at the following MMRC Member Institutions: the University of Michigan, Dana-Farber Cancer Institute, University of Chicago, Hackensack University Medical Center, and Roswell Park Cancer Institute, will evaluate the safety and efficacy of the combination in patients who have received one to three prior therapies. "Elotuzumab is a novel antibody that hits a target - CS1 - known to be highly expressed on myeloma cells with a... [read full story]
